Riskpilot← Back to searchSign inGet full accessVITUX PHARMA AS
ASActiveOrg 985318271Brynsveien 11-13, 0667 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20030 employeeswww.ayanda.com
Revenue 2024
NOK 0
EBITDA margin
—
-25% vs 2023
Equity ratio
97.0%
Financial strength
Net profit 2024
NOK 19K
-28% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -72K | -25% |
| Net profit | NOK 19K | -28% |
| Total assets | NOK 1,6M | +4% |
| Equity | NOK 1,6M | +1% |
| Employees | 0 | — |
Legal name
VITUX PHARMA AS
Org number
985318271
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31. januar 2003
Share capital
NOK 2 441 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Investere og utvikle næringsvirksomhet innen marin bioprospektering.
Address
Brynsveien 11-13, 0667 Oslo
Website
www.ayanda.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 729 | 1 350 | 1 388 | 1 511 | 1 781 | 934 | 478 | 0 | 0 | 0 | 165 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −713 | −587 | −329 | −537 | −923 | −593 | −319 | 1 | −0 | −1 | −43 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 45 | 171 | −173 | −604 | −976 | −586 | −399 | −103 | −87 | −103 | −60 | −25 | −48 | −48 | −64 | −57 | −72 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −1 209 | −1 592 | −18 960 | −3 510 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 45 | 171 | −173 | −604 | −976 | −586 | −1 609 | −1 695 | −19 047 | −3 614 | −60 | −25 | −48 | −48 | −64 | −57 | −72 |
| Net financials | −5 | −9 | −13 | −28 | 5 | −21 | −86 | 9 | 63 | 2 | 1 | 22 | 20 | 21 | 59 | 84 | 91 |
| Profit before tax | 40 | 162 | −186 | −631 | −971 | −606 | −1 695 | −1 686 | −18 984 | −3 612 | −59 | −2 | −27 | −27 | −5 | 26 | 19 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 40 | 162 | −186 | −631 | −971 | −606 | −1 695 | −1 686 | −18 984 | −3 612 | −59 | −2 | −27 | −27 | −5 | 26 | 19 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 661 | 2 242 | 3 883 | 8 717 | 9 627 | 14 102 | 15 610 | 20 185 | 16 967 | 6 182 | 1 623 | 1 603 | 1 588 | 1 549 | 1 562 | 1 570 | 1 638 |
| Equity | 1 374 | 1 536 | 1 350 | 719 | 4 748 | 4 141 | 2 446 | 3 760 | 276 | 1 664 | 1 605 | 1 603 | 1 576 | 1 549 | 1 544 | 1 570 | 1 589 |
| Long-term debt | 0 | 500 | 1 500 | 2 750 | 2 324 | 2 505 | 6 749 | 13 809 | 13 879 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 287 | 206 | 1 033 | 5 248 | 2 555 | 7 456 | 6 415 | 2 616 | 2 811 | 4 468 | 18 | 0 | 13 | 0 | 19 | 0 | 50 |
| Total debt | 287 | 706 | 2 533 | 7 998 | 4 879 | 9 961 | 13 164 | 16 424 | 16 690 | 4 518 | 18 | 0 | 13 | 0 | 19 | 0 | 50 |
EBITDA margin
-7206000.0%
This company
15.8%
Market median
-45607695% vs market
20082024
Equity ratio
97.0%
This company
38.2%
Market median
+154% vs market
20082024
Return on equity
1.2%
This company
18.4%
Market median
-93% vs market
20082024
Net profit margin
1894500.0%
This company
8.1%
Market median
+23388789% vs market
20082024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Vitux Group As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Salvesen & Thams As
VITUX PHARMA AS Board members of VITUX PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stein-Are Sivertsen | Board of Directors | 0 companies |
| Klaus Wilhelm Neumann | Chairman | 0 companies |
| Camilla Engelberg Bakken | Board of Directors | 0 companies |